RXRX

Recursion Pharmaceuticals closed at $3.66, up 1.39% from the previous close. The stock’s recent performance shows a modest daily gain.

Needham analyst Gil Blum keeps a Buy rating on Recursion Pharmaceuticals and maintains an $8 price target. The recommendation suggests confidence in the company’s prospects.

The headline questions whether Recursion’s current share price reflects its sales, noting an 80.5% drop over five years. It highlights concerns about the company’s valuation relative to its business scale.

After Sanofi’s first milestone payment, Recursion’s share price has been volatile, falling 16.7% on the day and 20.5% over the past week. The article notes the stock’s recent rough trading.

Sanofi exercised its option on Recursion’s first immunology candidate, triggering a $10 million milestone and moving the program into phase 1 trials. Recursion also reported positive updates for REC-4881 and REC-1245.